Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm Open-label Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BI 3000202 in Adult Patients With Selected Type 1 Interferonopathies

NCT06878365 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06878365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06878365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm Open-label Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BI 3000202 in Adult Patients With Selected Type 1 Interferonopathies
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 29, 2025
Completion date
December 7, 2026
Enrollment
16 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 interferonopathies